Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market
Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1 Agonist at BIO 2024
Laxxon Medical to Participate in the World Orphan Drug Congress USA 2024
Laxxon Medical to Participate in 23rd Annual Needham Virtual Health Conference
Laxxon Medical Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms
Laxxon Medical to Participate in 26th Annual Needham Growth Conference
Laxxon Medical to Attend 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
Laxxon Medical joins German Accelerator’s Southeast Asia Market Access Class of 2023
Laxxon Medical to Attend BIO-Europe Munich 2023
Laxxon Medical and CU Innovations at Anschutz Medical Campus Announce Strategic Partnership
3D Screen Printing Technology Enables Fabrication of Oral Drug Dosage Forms
Laxxon Medical to Participate in 2023 BIO International Convention
Laxxon Medical Announces Formation of Scientific Advisory Board with Renowned Pharmaceutical Experts
Laxxon Medical's Commitment to Meeting and Exceeding CGMP Regulations In 3D Printed Pharmaceuticals
CSO Achim Schneeberger Discusses the Development of Laxxon's Levodopa Project
Interview with Laxxon COO Klaus Kuehne
Hovione and Laxxon Medical Partnership Announced
Laxxon Medical to Participate in the BIO CEO & Investor Conference
Laxxon Medical to Participate in 25th Annual Needham Growth Conference
Evonik & Laxxon: An Innovative Force